These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
619 related articles for article (PubMed ID: 3133812)
1. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system. Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812 [TBL] [Abstract][Full Text] [Related]
2. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Siegbahn A; Ruusuvaara L Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043 [TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females. Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623 [TBL] [Abstract][Full Text] [Related]
4. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism. Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786 [TBL] [Abstract][Full Text] [Related]
5. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects. Stegnar M; Mavri A Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828 [TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium. Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554 [TBL] [Abstract][Full Text] [Related]
7. Diurnal variation of the fibrinolytic system. Grimaudo V; Hauert J; Bachmann F; Kruithof EK Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085 [TBL] [Abstract][Full Text] [Related]
8. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay. Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285 [TBL] [Abstract][Full Text] [Related]
9. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580 [TBL] [Abstract][Full Text] [Related]
10. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor]. Köhler M; Miyashita C Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347 [TBL] [Abstract][Full Text] [Related]
11. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity]. Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies. Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431 [TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes. Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392 [TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic activity in peripheral atherosclerosis in the elderly. van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006 [TBL] [Abstract][Full Text] [Related]
15. [Fibrinolytic activity and tissue plasminogen activator level in healthy individuals prior to and after a ten-minute venous stasis]. Kubicka A; Libura M; Sacha T; Swadźba J; Undas A; Wandzilak M Pol Tyg Lek; 1993 Feb 1-8; 48(5-6):116-9. PubMed ID: 8361905 [TBL] [Abstract][Full Text] [Related]
16. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164 [TBL] [Abstract][Full Text] [Related]
17. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies. Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090 [TBL] [Abstract][Full Text] [Related]
18. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease. Philips M; Juul AG; Selmer J; Lind B; Thorsen S Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392 [TBL] [Abstract][Full Text] [Related]
19. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis]. Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664 [TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator release in chronic venous hypertension due to heart failure. Keber I; Keber D; Stegnar M; Vene N Thromb Haemost; 1992 Sep; 68(3):321-4. PubMed ID: 1440498 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]